pcDNA3-sACE2(WT)-8his Citations (10)

Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4. PubMed Journal

---

Articles Citing pcDNA3-sACE2(WT)-8his

Articles
The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. Procko E. bioRxiv. 2020 May 11. doi: 10.1101/2020.03.16.994236. PubMed
Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants. Zhang L, Dutta S, Xiong S, Chan M, Chan KK, Fan TM, Bailey KL, Lindeblad M, Cooper LM, Rong L, Gugliuzza AF, Shukla D, Procko E, Rehman J, Malik AB. bioRxiv. 2021 Dec 22. doi: 10.1101/2021.12.21.473668. PubMed
Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2. Sci Rep. 2022 Jan 13;12(1):692. doi: 10.1038/s41598-021-03675-0. PubMed
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. bioRxiv. 2022 Mar 28. doi: 10.1101/2022.03.28.486075. PubMed
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen. Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Brown EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguere P, Alain T, Cote M, Paludan SR, Olagnier D, Bell JC, Azad T, Diallo JS. Mol Ther. 2022 Sep 7;30(9):2998-3016. doi: 10.1016/j.ymthe.2022.04.025. Epub 2022 May 6. PubMed
hACE2-Induced Allosteric Activation in SARS-CoV versus SARS-CoV-2 Spike Assemblies Revealed by Structural Dynamics. Chen C, Zhu R, Hodge EA, Diaz-Salinas MA, Nguyen A, Munro JB, Lee KK. ACS Infect Dis. 2023 Jun 9;9(6):1180-1189. doi: 10.1021/acsinfecdis.3c00010. Epub 2023 May 11. PubMed
Deglycosylated RBD produced in Pichia pastoris as a low-cost sera COVID-19 diagnosis tool and a vaccine candidate. Idrovo-Hidalgo T, Pignataro MF, Bredeston LM, Elias F, Herrera MG, Pavan MF, Foscaldi S, Suireszcz M, Fernandez NB, Wetzler DE, Pavan CH, Craig PO, Roman EA, Ruberto LAM, Noseda DG, Ibanez LI, Czibener C, Ugalde JE, Nadra AD, Santos J, D'Alessio C. Glycobiology. 2023 Nov 7:cwad089. doi: 10.1093/glycob/cwad089. PubMed
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern. Rubio AA, Baharani VA, Dadonaite B, Parada M, Abernathy ME, Wang Z, Lee YE, Eso MR, Phung J, Ramos I, Chen T, Nesr GE, Bloom JD, Bieniasz PD, Nussenzweig MC, Barnes CO. bioRxiv [Preprint]. 2024 May 6:2024.05.05.592584. doi: 10.1101/2024.05.05.592584. PubMed
Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera. Eliadis P, Mais A, Papazisis A, Loxa EK, Dimitriadis A, Sarrigeorgiou I, Backovic M, Agallou M, Zouridakis M, Karagouni E, Lazaridis K, Mamalaki A, Lymberi P. Vaccines (Basel). 2024 Aug 13;12(8):914. doi: 10.3390/vaccines12080914. PubMed
Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots. Berman K, Van Slyke G, Novak H, Rock JM, Bievenue R, Damjanovic AK, DeRosa KL, Mirabile G, Phipps K, Machowski J, Bialosuknia S, Giradin RC, Dupuis AP, Payne AF, Lee WT, McDonough KA, Parker MM, Styer LM, Mantis NJ. Microbiol Spectr. 2024 Oct 29;12(12):e0084624. doi: 10.1128/spectrum.00846-24. PubMed

If you have published an article using this material, please email us at to have your article added to this page.